These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 9651393)

  • 1. Topoisomerase IV catalysis and the mechanism of quinolone action.
    Anderson VE; Gootz TD; Osheroff N
    J Biol Chem; 1998 Jul; 273(28):17879-85. PubMed ID: 9651393
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Action of quinolones against Staphylococcus aureus topoisomerase IV: basis for DNA cleavage enhancement.
    Anderson VE; Zaniewski RP; Kaczmarek FS; Gootz TD; Osheroff N
    Biochemistry; 2000 Mar; 39(10):2726-32. PubMed ID: 10704224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quinolones inhibit DNA religation mediated by Staphylococcus aureus topoisomerase IV. Changes in drug mechanism across evolutionary boundaries.
    Anderson VE; Zaniewski RP; Kaczmarek FS; Gootz TD; Osheroff N
    J Biol Chem; 1999 Dec; 274(50):35927-32. PubMed ID: 10585479
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of quinolone derivatives on eukaryotic topoisomerase II. A novel mechanism for enhancement of enzyme-mediated DNA cleavage.
    Robinson MJ; Martin BA; Gootz TD; McGuirk PR; Moynihan M; Sutcliffe JA; Osheroff N
    J Biol Chem; 1991 Aug; 266(22):14585-92. PubMed ID: 1650363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of novel fluoroquinolones on the catalytic activities of eukaryotic topoisomerase II: Influence of the C-8 fluorine group.
    Robinson MJ; Martin BA; Gootz TD; McGuirk PR; Osheroff N
    Antimicrob Agents Chemother; 1992 Apr; 36(4):751-6. PubMed ID: 1323952
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activities of trovafloxacin compared with those of other fluoroquinolones against purified topoisomerases and gyrA and grlA mutants of Staphylococcus aureus.
    Gootz TD; Zaniewski RP; Haskell SL; Kaczmarek FS; Maurice AE
    Antimicrob Agents Chemother; 1999 Aug; 43(8):1845-55. PubMed ID: 10428901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quinolones share a common interaction domain on topoisomerase II with other DNA cleavage-enhancing antineoplastic drugs.
    Elsea SH; Westergaard M; Burden DA; Lomenick JP; Osheroff N
    Biochemistry; 1997 Mar; 36(10):2919-24. PubMed ID: 9062121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The p53 tumor suppressor stimulates the catalytic activity of human topoisomerase IIalpha by enhancing the rate of ATP hydrolysis.
    Kwon Y; Shin BS; Chung IK
    J Biol Chem; 2000 Jun; 275(24):18503-10. PubMed ID: 10764786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overcoming target-mediated quinolone resistance in topoisomerase IV by introducing metal-ion-independent drug-enzyme interactions.
    Aldred KJ; Schwanz HA; Li G; McPherson SA; Turnbough CL; Kerns RJ; Osheroff N
    ACS Chem Biol; 2013 Dec; 8(12):2660-8. PubMed ID: 24047414
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of topoisomerase II-targeted drugs on enzyme-mediated DNA cleavage and ATP hydrolysis: evidence for distinct drug interaction domains on topoisomerase II.
    Robinson MJ; Corbett AH; Osheroff N
    Biochemistry; 1993 Apr; 32(14):3638-43. PubMed ID: 8385484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of eukaryotic topoisomerase II cleavage sites in the presence of the quinolone CP-115,953 reveals drug-dependent and -independent recognition elements.
    Spitzner JR; Chung IK; Gootz TD; McGuirk PR; Muller MT
    Mol Pharmacol; 1995 Aug; 48(2):238-49. PubMed ID: 7651357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNA gyrase and topoisomerase IV on the bacterial chromosome: quinolone-induced DNA cleavage.
    Chen CR; Malik M; Snyder M; Drlica K
    J Mol Biol; 1996 May; 258(4):627-37. PubMed ID: 8636997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bacterial topoisomerases, anti-topoisomerases, and anti-topoisomerase resistance.
    Hooper DC
    Clin Infect Dis; 1998 Aug; 27 Suppl 1():S54-63. PubMed ID: 9710672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cloning and characterization of the parC and parE genes of Streptococcus pneumoniae encoding DNA topoisomerase IV: role in fluoroquinolone resistance.
    Pan XS; Fisher LM
    J Bacteriol; 1996 Jul; 178(14):4060-9. PubMed ID: 8763932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug interactions with Bacillus anthracis topoisomerase IV: biochemical basis for quinolone action and resistance.
    Aldred KJ; McPherson SA; Wang P; Kerns RJ; Graves DE; Turnbough CL; Osheroff N
    Biochemistry; 2012 Jan; 51(1):370-81. PubMed ID: 22126453
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanism of quinolone action. A drug-induced structural perturbation of the DNA precedes strand cleavage by topoisomerase IV.
    Marians KJ; Hiasa H
    J Biol Chem; 1997 Apr; 272(14):9401-9. PubMed ID: 9083078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Merbarone inhibits the catalytic activity of human topoisomerase IIalpha by blocking DNA cleavage.
    Fortune JM; Osheroff N
    J Biol Chem; 1998 Jul; 273(28):17643-50. PubMed ID: 9651360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DNA cleavage and religation by human topoisomerase II alpha at high temperature.
    Bromberg KD; Osheroff N
    Biochemistry; 2001 Jul; 40(28):8410-8. PubMed ID: 11444988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Type II topoisomerases as targets for quinolone antibacterials: turning Dr. Jekyll into Mr. Hyde.
    Anderson VE; Osheroff N
    Curr Pharm Des; 2001 Mar; 7(5):337-53. PubMed ID: 11254893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Defining functional drug-interaction domains on topoisomerase II by exploiting mechanistic differences between drug classes.
    Osheroff N; Corbett AH; Elsea SH; Westergaard M
    Cancer Chemother Pharmacol; 1994; 34 Suppl():S19-25. PubMed ID: 8070023
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.